NCT00599417 PulmonarOM (Bacterial Lysates) in Respiratory Tract Infections Status COMPLETED Phase PHASE4
NCT00598858 Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate Status WITHDRAWN Phase PHASE2
NCT00596687 Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery Status COMPLETED Phase PHASE4
NCT00596206 Leflunomide EfficAcy Response Related to Dosing Regimen in Early Rheumatoid Arthritis Status COMPLETED Phase PHASE3
NCT00593853 Efficacy Study of Methylphenidate Hydrochloride to Reduce Fatigue in Prostate Cancer Patients Receiving Hormone Therapy Status TERMINATED Phase PHASE2
NCT00591149 Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer Status TERMINATED Phase PHASE2
NCT00591123 Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia Status COMPLETED Phase PHASE2
NCT00590044 Basal Insulin in the Management of Patients With Diabetic Ketoacidosis (DKA) Status COMPLETED Phase PHASE4
NCT00589420 Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy Status COMPLETED Phase PHASE2
NCT00585182 Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT Status COMPLETED Phase PHASE4
NCT00585078 Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Status COMPLETED Phase PHASE2
NCT00583258 A Randomized Study of Whether Alfuzosin(Xatral) Helps in the Passage of Kidney Stones Status WITHDRAWN Phase NA
NCT00582582 Study of Docetaxel With Doxercalciferol or Placebo for Advanced Prostate Cancer Status TERMINATED Phase PHASE2
NCT00582309 Comparative Trial Between 3 Types of Insulin Infusion Protocols Status COMPLETED Phase NA
NCT00580216 Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation Status TERMINATED Phase PHASE3
NCT00580073 Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum Status TERMINATED Phase PHASE2
NCT00577850 Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose Status COMPLETED Phase PHASE1
NCT00577837 Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD Status COMPLETED Phase PHASE2
NCT00577421 Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO Status COMPLETED Phase PHASE3